inmune
bio
inc
awarded
million
nih
small
business
innovation
research
grant
support
phase
study
patients
treatment
resistant
depression
patient
blinded
randomized
phase
study
use
neuroimaging
technology
study
complex
biology
treatment
resistant
disease
study
supports
inmune
bio
approach
treating
inflammation
common
mechanism
neurologic
disease
accompanying
key
opinion
leader
webinar
hosted
september
discuss
role
neuroinflammation
treatment
resistant
depression
la
jolla
globe
newswire
inmune
bio
nasdaq
inmb
company
immunology
company
focused
developing
treatments
harness
patient
innate
immune
system
fight
disease
today
announced
received
million
small
business
innovation
research
sbir
grant
national
institutes
health
nih
subject
terms
grant
company
receive
year
next
year
balance
received
grant
support
phase
study
patients
treatment
resistant
depression
study
entitled
effects
next
generation
tnf
inhibitor
deficits
reward
circuitry
motivation
depression
conducted
two
sites
emory
university
school
medicine
atlanta
university
alabama
birmingham
treatment
resistant
depression
major
problem
affecting
seven
million
patients
alone
said
cj
barnum
head
neurosciences
inmune
bio
grant
collaboration
two
thought
leaders
difficult
treat
condition
professor
andrew
miller
associate
professor
jennifer
felger
emory
university
miller
foremost
expert
neuroinflammation
depression
published
first
study
demonstrating
treatment
could
improve
depressive
symptoms
patients
high
levels
inflammatory
marker
protein
crp
biomarker
used
select
patients
study
addition
felger
discovered
connection
two
regions
brain
vital
feelings
pleasure
motivation
lost
depressed
patients
inflammation
hypothesis
restore
selective
inhibitor
soluble
tumor
necrosis
factor
stnf
key
inflammatory
cytokine
implicated
causing
neuroinflammation
patients
neurologic
disease
including
treatment
resistant
depression
alzheimer
disease
neurodegenerative
diseases
phase
blinded
randomized
study
enroll
patients
treatment
resistant
depression
biomarkers
inflammation
anhedonia
inability
feel
pleasure
neuroimaging
biomarkers
used
measure
response
patients
studied
functional
mri
determine
functional
connectivity
brain
circuitry
improved
reversing
neuroinflammation
translates
improvements
clinical
symptoms
anhedonia
motivation
rj
tesi
chief
executive
officer
inmune
bio
added
award
reinforces
one
inmune
bio
fundamental
drug
development
tenets
targeting
underlying
biology
target
diverse
group
diseases
caused
inflammation
phase
study
evaluate
potential
utility
treat
biology
neuroinflammation
believe
beneficial
effect
patients
suffering
treatment
resistant
depression
recently
presented
preliminary
data
demonstrating
decreased
neuroinflammation
alzheimer
disease
believe
findings
provide
strong
rationale
study
neuroinflammatory
indication
company
also
host
key
opinion
leader
kol
webinar
et
tuesday
september
provide
additional
information
role
neuroinflammation
treatment
resistant
depression
webinar
feature
presentations
charles
raison
professor
department
psychiatry
university
wisconsin
madison
john
schneider
chief
executive
officer
principal
avalon
health
economics
details
provided
near
future
disclaimer
research
reported
publication
supported
national
institute
mental
health
national
institutes
health
award
number
content
solely
responsibility
authors
necessarily
represent
official
views
national
institutes
health
treatment
resistant
depression
major
depressive
disorder
mdd
highly
prevalent
difficult
treat
one
disabling
medical
conditions
worldwide
according
national
institutes
health
estimated
million
adults
experience
mdd
year
least
one
third
approximately
seven
million
patients
considered
treatment
resistant
depression
trd
defined
persistence
depressive
symptoms
patient
failed
respond
two
previous
lines
conventional
treatment
adequate
dose
duration
patients
trd
incur
highest
direct
indirect
medical
costs
among
mdd
costs
increase
severity
trd
patients
twice
likely
hospitalized
cost
hospitalization
six
times
mean
total
cost
depressed
patients
treatment
resistant
account
nearly
billion
total
inhibitor
tumor
necrosis
factor
tnf
acts
differently
currently
existing
tnf
inhibitors
neutralizes
soluble
tnf
stnf
without
affecting
tnf
tmtnf
tnf
receptors
could
substantial
beneficial
effects
patients
neurologic
disease
decreasing
neuroinflammation
information
importance
targeting
neuroinflammation
brain
improve
cognitive
function
restore
neuronal
communication
visit
section
inmune
bio
website
inmune
bio
inmune
bio
inc
publicly
traded
nasdaq
inmb
biotechnology
company
focused
developing
treatments
target
innate
immune
system
fight
disease
inmune
bio
two
product
platforms
product
platform
utilizes
technology
selectively
neutralize
soluble
tnf
key
driver
innate
immune
dysfunction
mechanistic
target
many
diseases
currently
developed
complications
cancer
alzheimer
treatment
resistant
depression
nash
natural
killer
cell
priming
platform
includes
aimed
priming
patient
nk
cells
eliminate
minimal
residual
disease
patients
cancer
inmune
bio
product
platforms
utilize
precision
medicine
approach
treatment
wide
variety
hematologic
malignancies
solid
tumors
chronic
inflammation
learn
please
visit
forward
looking
statements
clinical
trials
early
stages
assurance
specific
outcome
achieved
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
contained
herein
based
current
expectations
subject
number
risks
uncertainties
actual
results
timing
certain
events
circumstances
may
differ
materially
described
statements
result
risks
uncertainties
livnate
inkmune
still
clinical
trials
preparing
start
clinical
trials
approved
assurance
approved
specific
results
achieved
two
platforms
beginning
clinical
trials
assurance
success
trials
factors
could
cause
actual
future
results
differ
materially
current
expectations
include
limited
risks
uncertainties
relating
company
ability
produce
drug
clinical
trials
availability
substantial
additional
funding
company
continue
operations
conduct
research
development
clinical
studies
future
product
commercialization
company
business
research
product
development
regulatory
approval
marketing
distribution
plans
strategies
factors
identified
described
detail
company
filings
securities
exchange
commission
including
company
annual
report
form
company
quarterly
reports
form
company
current
reports
form
company
assumes
obligation
update
statements
order
reflect
event
circumstance
may
arise
date
release
mrazek
et
al
review
clinical
economic
societal
burden
resistant
depression
psychiatr
serv
ionescu
et
al
pharmacological
approaches
challenge
depression
dialogues
clin
neurosci
inmune
bio
contact
david
moss
cfo
dmoss
investor
contact
chuck
padala
lifesci
advisors
chuck
media
contact
meredith
sosulski
lifesci
communications
msosulski
